[1(2H),4'-Bipyridin]-2-one, 3-chloro-4-[(3,5-difluoro-2-pyridinyl)methoxy]-2'-[2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl]-5',6-dimethyl-, (2'S)-

Request For Quotation
[1(2H),4'-Bipyridin]-2-one, 3-chloro-4-[(3,5-difluoro-2-pyridinyl)methoxy]-2'-[2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl]-5',6-dimethyl-, (2'S)- Suppliers list
Company Name: Chengdu PEIP Pharmaceutical Technology Co., LTD.  Gold
Tel: 028-61715638 18011352545
Email: 1242335275@qq.com
Company Name: WUHAN SUN-SHINE BIO-TECHNOLOGY Co., Ltd.  
Tel: 17702719238
Email: sales@sun-shinechem.com
Company Name: Nanjing Chemlin Chemical Co., Ltd  
Tel: 025-83697070 13770331960
Email: info@chemlin.com.cn
Company Name: Shanghai Lollane Biological Technology Co.,Ltd.  
Tel: 021-52996696，15000506266 15000506266
Email:
Company Name: Shanghai EFE Biological Technology Co., Ltd.  
Tel: 021-65675885 18964387627
Email: info@efebio.com

[1(2H),4'-Bipyridin]-2-one, 3-chloro-4-[(3,5-difluoro-2-pyridinyl)methoxy]-2'-[2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl]-5',6-dimethyl-, (2'S)- manufacturers

  • Zunsemetinib
  • Zunsemetinib pictures
  • $66.00
  • 2026-07-27
  • CAS:1640282-42-3
  • Purity: 99.77%
  • Supply Ability: 10g
[1(2H),4'-Bipyridin]-2-one, 3-chloro-4-[(3,5-difluoro-2-pyridinyl)methoxy]-2'-[2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl]-5',6-dimethyl-, (2'S)- Basic information
Product Name:[1(2H),4'-Bipyridin]-2-one, 3-chloro-4-[(3,5-difluoro-2-pyridinyl)methoxy]-2'-[2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl]-5',6-dimethyl-, (2'S)-
Synonyms:[1(2H),4'-Bipyridin]-2-one, 3-chloro-4-[(3,5-difluoro-2-pyridinyl)methoxy]-2'-[2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl]-5',6-dimethyl-, (2'S)-;ATI-450;1(2H),4'-Bipyridin]-2-one, 3-chloro-4-[(3,5-difluoro-2-pyridinyl)methoxy]-2'-[2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl]-5',6-dimethyl-, (2'S)-;Zunsemetinib (ATI-450;[1(2H),4'-BIPYRIDIN]-2-ONE, 3-CHLORO-4-[(3,5-DIFLUORO-2-PYRIDINYL)METHOXY]-2'-[2-(1-HYDROXY-1-METHY;(2'S)-3-Chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one;Zunsemetinib
CAS:1640282-42-3
MF:C25H22ClF2N5O3
MW:513.93
EINECS:
Product Categories:
Mol File:1640282-42-3.mol
[1(2H),4'-Bipyridin]-2-one, 3-chloro-4-[(3,5-difluoro-2-pyridinyl)methoxy]-2'-[2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl]-5',6-dimethyl-, (2'S)- Structure
[1(2H),4'-Bipyridin]-2-one, 3-chloro-4-[(3,5-difluoro-2-pyridinyl)methoxy]-2'-[2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl]-5',6-dimethyl-, (2'S)- Chemical Properties
Boiling point 680.4±55.0 °C(Predicted)
density 1.45±0.1 g/cm3(Predicted)
storage temp. Store at -20°C
solubility DMSO:100.0(Max Conc. mg/mL);194.58(Max Conc. mM)
pka13.52±0.29(Predicted)
form Solid
color White to yellow
InChIInChI=1S/C25H22ClF2N5O3/c1-13-10-30-18(17-5-6-29-24(32-17)25(3,4)35)9-20(13)33-14(2)7-21(22(26)23(33)34)36-12-19-16(28)8-15(27)11-31-19/h5-11,35H,12H2,1-4H3
InChIKeyFQPQMJULRZINPV-UHFFFAOYSA-N
SMILESO=C1C(=C(OCC2N=CC(F)=CC=2F)C=C(C)N1C1=C(C=NC(C2C=CN=C(C(O)(C)C)N=2)=C1)C)Cl
Safety Information
MSDS Information
[1(2H),4'-Bipyridin]-2-one, 3-chloro-4-[(3,5-difluoro-2-pyridinyl)methoxy]-2'-[2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl]-5',6-dimethyl-, (2'S)- Usage And Synthesis
UsesZunsemetinib (CDD-450) is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway inhibitor. Zunsemetinib can be used for the research of immuno-inflammatory diseases[1].
in vivo

Zunsemetinib (1,000 ppm; p.o.) blocks LPS-induced TNF-α expression persisted for up to 4 weeks after dosing[1].
Zunsemetinib (10 and 20 mg/kg; p.o.) increases bone density[1].
Zunsemetinib prevents osteopenia in NOM IDc mice through inhibition of osteoclastogenesis[1].

Animal Model:8-week-old WT female mice[1]
Dosage:1,000 ppm
Administration:P.o.
Result:Blocked LPS-induced TNF-α expression persisted for up to 4 weeks after dosing.
Animal Model:Rats[1]
Dosage:10 and 20 mg/kg
Administration:P.o.
Result:Increased bone density.
References[1] Zunsemetinib (ATI-450) – Investigational oral MK2 pathway inhibitor
[2] Aclaris Therapeutics Announces ATI-450 (MK2 pathway Inhibitor) publication in Journal of Experimental Medicine
[3] Wang C, et al. Selective inhibition of the p38α MAPK-MK2 axis inhibits inflammatory cues including inflammasome priming signals. J Exp Med. 2018;215(5):1315-1325. DOI:10.1084/jem.20172063
[1(2H),4'-Bipyridin]-2-one, 3-chloro-4-[(3,5-difluoro-2-pyridinyl)methoxy]-2'-[2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl]-5',6-dimethyl-, (2'S)- Preparation Products And Raw materials
Tag:[1(2H),4'-Bipyridin]-2-one, 3-chloro-4-[(3,5-difluoro-2-pyridinyl)methoxy]-2'-[2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl]-5',6-dimethyl-, (2'S)-(1640282-42-3) Related Product Information
SB242235 3-[N-(2-Hydroxyacetyl)-4-piperidyl]-4-(4-pyrimidinyl)-5-(4-chlorophenyl)pyrazole 4',7-Dimethoxy-5-hydroxyflavone p38-α MAPK-IN-1 Ginsenoside CK C-PEPTIDE (HUMAN)